Oliver A. Cornely. Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2. Centre for Clinical Research

Similar documents
What have we learned about systemic antifungals currently available on the market?

Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients

Optimal Management of Invasive Aspergillosis in the Context of New Guidelines in High Risk Haematological Patients

TOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR

ESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole

Antifungal Therapy in Leukemia Patients

Treatment and Prophylaxis

HOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS?

Empirical Antifungal Therapy 2009 Update of ECIL-1 / ECIL-2 Guidelines O. Marchetti, C. Cordonnier, T. Calandra

New Directions in Invasive Fungal Disease: Therapeutic Considerations

Primary prophylaxis of invasive fungal infection in patients with haematological diseases

Current options of antifungal therapy in invasive candidiasis

Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?

Treatment Guidelines for Invasive Aspergillosis

Treatment Guidelines for Invasive Aspergillosis

MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author

PROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino

How Can We Prevent Invasive Fungal Disease?

Amphotericin B Lipid Complex (Abelcet ) 05/06

Therapy of Hematologic Malignancies Period at high risk of IFI

TREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS. Part I: EMPIRICAL THERAPY

Isavuconazole. Lepak et al 2013 Antimicrob Agents Chemother 57: Lepak et al 2013 Antimicrob Agents Chemother 57:

Micafungin, a new Echinocandin: Pediatric Development

Aspergillosis in the critically ill patient

Fungal Infection in the ICU: Current Controversies

EMA Pediatric Web Synopsis Protocol A November 2011 Final PFIZER INC.

Challenges and controversies of Invasive fungal Infections

Application of PK/PD concepts and the role of TDM in the management of patients with fungal disease. The role of combination therapy as of May 2011

Considerations for Antifungal Management in Pediatric Cancer Patients

amphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET

No Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany

Introduction. J Antimicrob Chemother 2011; 66 Suppl 1: i25 35 doi: /jac/dkq439. Nick Freemantle 1 *, Puvan Tharmanathan 2 and Raoul Herbrecht 3

posaconazole, or prayers

I am against to TDM in critically ill patient

Guidelines for Antifungal Therapy for Invasive Fungal Infection. National Comprehensive Cancer Care Network

Is monitoring of azole concentrations of clinical value in patients with haematological malignancies?

Antifungal prophylaxis in haematology patients: the role of voriconazole

Antifungals and current treatment guidelines in pediatrics and neonatology

ADVANCES AND CHALLENGES IN HEMATOLOGY. Invasive fungal disease management in febrile neutropenia

The Hospital for Sick Children Technology Assessment at SickKids (TASK) ABSTRACT

The Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY

Cigna Drug and Biologic Coverage Policy

MAJOR ARTICLE. Outcomes of Patients with IA and AML-MDS CID 2008:47 (15 December) 1507

Antifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary

Combination Antifungal Therapy for Invasive Aspergillosis

Evaluation of hypokalemia and potassium supplementation during administration of liposomal amphotericin B

How Can We Tailor Antifungal Therapy?

Fungal infections. Ematologia. Corrado Girmenia. Ematologia, Azienda Policlinico Umberto I Sapienza University of Rome, Italy

INFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU. Claudio Viscoli Professor of Infectious Disease University of Genoa

Department of Pediatric Hematology/Oncology, University Children s Hospital Tübingen, Hoppe-Seyler-Strß 1, Tübingen, Germany 2

Rezafungin: A Novel Echinocandin. Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018

Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong

When is failure failure?

Management and diagnostic guidelines for fungal diseases in infectious diseases and clinical microbiology: critical appraisal

Broad spectrum triazoles: which drug and when?

Condition First line Alternative Comments Candidemia Nonneutropenic adults

ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS

Trends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients. Saturday, April 18, 2015 Charlottetown, P.E.I.

Dutch Working Party on Antibiotic Policy. SWAB Guidelines for the Management of Invasive Fungal Infections. September 2008

Monitoring of Voriconazole levels at University Hospital. Jason Bowling, MD Rachel Rivera, MD

Prophylaxis Limitations: Challenges in the Management of Invasive Aspergillosis

Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan

TIMM 2013 Role of non-culture biomarkers for detection of fungal infections

MANAGEMENT OF PULMONARY MYCOSIS

NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003

Management Of Invasive Fungal Infections In Immunosupressed Hosts

Invasive Pulmonary Aspergillosis in

London New Drugs Group APC/DTC Briefing

Antifungal Pharmacodynamics A Strategy to Optimize Efficacy

WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?

Invasive aspergillosis (IA) is a leading cause of infectious death in

Case Studies in Fungal Infections and Antifungal Therapy

CD101: A Novel Echinocandin

Aspergillosis in Pediatric Patients

Invasive aspergillosis: Is treatment with inexpensive amphotericin B cost-saving if expensive voriconazole is only used on demand?

Invasive Aspergillosis in India: Unique Challenges. Dr Rajeev Soman Consultant Physician PD Hinduja Hospital Mumbai

Indre Vengalyte MD¹, Regina Pileckyte MD¹, Laimonas Griskevicius MD PhD 1, 2

II Raad, HA Hanna, M Boktour, Y Jiang, HA Torres, C Afif, DP Kontoyiannis and RY Hachem

The Outcome of Invasive Fusariosis Has Improved in the Last Decade

Use of Antifungal Drugs in the Year 2006"

Solid organ transplant patients

Use of Antifungals in the Year 2008

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

Cancer Medicine. Introduction. Open Access ORIGINAL RESEARCH

ECIL ESCMID Aspergillus Guidelines

Monitorization, Separation and Quantification of Antifungals used for Invasive Aspergillosis Treatment by High Performance Thin Layer Chromatography

Is pre-emptive therapy a realistic approach?

14/05/ <500/mm 3

EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS

Managing breakthrough Invasive Aspergillosis Livio Pagano

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR

Disclosure of Potential Conflicts of Interest: How do anti-infectiveguidelines. patients with GvHD? Fungal infections

Voriconazole October 2015 Risk Management Plan. Voriconazole

Fungal Infections in Neutropenic Hematological Disorders

Therapeutic Options: Where do we stand? Where do we go?

Top 5 papers in clinical mycology

Combination Antifungal Therapy for Invasive Pulmonary Aspergillosis in a Heart Transplant Recipient

Transcription:

Management of Confirmed Aspergillosis Oliver A. Cornely 1 Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2 Centre for Clinical Research University of Cologne

Global the Aspergillus Study Group and the

Successful Response Rate Voriconazole n = 144 c-amb n = 133 Week 12 (95% CI 10-33%) 76 (53%) 42 (32%) Voriconazole is superior to amphotericin B deoxycholate.

Overall Survival 100% Voriconazole 80% 71% % surv vival 60% 40% log rank, p = 0.015 58% Amphotericin B 20% 0% 0 2 4 6 8 10 12 Weeks Number of patients at risk Voriconazole 144 131 125 117 111 107 102 c-amb 133 117 99 87 84 80 77

What do European Guidelines Propose? Herbrecht R et al. EJC 2007; S49-59.

ECIL-1 Products Rating Voriconazole Amphotericin B deoxycholate Liposomal amphotericin B Amphotericin B lipid complex Amphotericin B colloidal dispersion Caspofungin Itraconazole Combination therapy AI DI BI BII DI CIII CIII DIII Herbrecht et al., Eur J Cancer Supplement, 2007; http://www.ichs.org

Cornely O. et al. Clinical Infectious Diseases 2007; Cornely 44:1289 97. et al. CID 2007. 2007; 44:1289 97.

AmBiLoad Trial Design Invasive Filamentous Fungal Infection Randomization L-AmB d1-14 L-AmB 3 mg/kg double-blind 10 mg/kg L-AmB 3mg/kg Cornely O. et al. Clinical Infectious Diseases 2007; 44:1289 97.

Patient 1001 - probable ALL Steroids Neutropenia Fever >72h? Galactomannan 1

Probable Invasive Aspergillosis AML Neutropenia Fever >72h Cough Dyspnea yp Pleuritis Galactomannan 1

Baseline Characteristics AmBi-3mg N=107 AmBi-10mg N=94 Age (mean, yrs) [range] 50.9 [15-76] 50.4 [2-78] Sex: M/F (%) 57/43 67/33 Hematological Malignancies 1 99 (93) 87 (93) Controlled 36/99 (36) 26/85 (31) Uncontrolled 2 63/99 (64) 59/85 (69) Allo-SCT 17 (16) 18 (19) Auto-SCT 1 (1) 4 (4) Solid Organ Transplant 1 (1) 0 HIV 2 (2) 2 (2) Neutropenia at baseline 76 (71) 71 (76) Cornely O. et al. Clinical Infectious Diseases 2007; 44:1289 97.

Overall Response at EOT N (%) L-AmB 3mg N=107 L-AmB 10mg N=94 Favorable 53 (50) 43 (46) CR 1 (1) 2 (2) PR 52 (49) 41 (44) Unfavorable Stable 8 (7) 5 (5) Failure 36 (34) 36 (38) Not evaluable 10 (9) 10 (11) Cornely O. et al. Clinical Infectious Diseases 2007; 44:1289 97.

Conclusions In a highly immunocompromised population 93% hematological malignancies 42% neutropenia persisting at EOT 1. L-AmB 3mg/kg as 1st line treatment for aspergillosis resulted in a 50% success rate 72% 12 week survival rate 2. L-AmB 10 mg/kg did not improve response or survival was associated with higher rates of toxicity Cornely O. et al. Clinical Infectious Diseases 2007; 44:1289 97.

What do US Guidelines Propose? Walsh T, et al. Clinical Infectious Diseases 2008; 46:327 60. Walsh TJ et al. CID 2008; 46: 327-60.

IDSA Guidelines 2000 2008: Primary Therapy of Invasive Aspergillosis i IDSA Guidelines 2000 Amphotericin B Liposomal amphotericin B Voriconazole Amphotericin B has been the standard of treatment in invasive aspergillosis, particularly for life-threatening and severe infections. In well-characterized patients, the overall response rate has been 37% (range, 14% 83%) The lipid based formulations are indicated for patients with invasive aspergillosis who develop nephrotoxicity while receiving amphotericin IDSA Guidelines 2008 Preferred therapy-voriconazole ole is recommended for the primary treatment of invasive aspergillosis in most patients Rating AII 1 Rating AI 2,3 Liposomal amphotericin B Alternative-A ti Arandomized d trial comparing two dosages of liposomal amphotericin B showed similar efficacy in both arms, suggesting that liposomal therapy could be considered as alternative primary therapy in some patients AI 2,3 1 Stevens D, et al. Clinical Infectious Diseases 2000;30:696 709 2 Patterson W, et al. IDSA IA guidelines 2007, ICAAC 2007 3 Walsh T, et al. Clinical Infectious Diseases 2008; 46:327 60.

Survival and Sub-group Analyses from the AmBiLoad Trial New Insights

Survival Was Similar in Both Treatment Groups Cum mulative % of patient ts 100% 80% 60% 40% 20% 94% 91% 93% 88% Log rank p= 0.089 76% 69% 72% 59% 0% 0 2 4 6 8 10 12 Weeks L-AMB 3 mg/kg, g, n=107 L-AMB 10 mg/kg, g, n=94 Cornely O. et al. Clinical Infectious Diseases 2007; 44:1289 97.

Favorable Overall Response with L-AMB by Baseline Neutropenia Status t 3 mg/kg g per day 10 mg/kg g per day 100% % of patie ents 80% 60% 40% 43% 42% 67% 57% 20% 0% Neutropenia No neutropenia Cornely O, et al. Poster P122. 2nd Advances Against Aspergillosis, Athens, Greece, Feb 2006.

Stepwise Logistic Regression Analysis 12 Week Survival

Patients with Allo SCT Had a Lower Survival at 12 Weeks 80% 71%* survival f patients % o 60% 40% 20% 40% 0% No Allo SCT Allo SCT *P<0.001 Cornely O, et al. Poster P122. 2nd Advances Against Aspergillosis, Athens, Greece, Feb 2006.

Patients with Uncontrolled Malignancy Had a Lower Survival with L-AmB at 12 Weeks Uncontrolled Malignancy Controlled Malignancy Heme Malignancy (all) 54% 81% * Leukemias (all) 57% 82% * 82% Acute Leukemias * 63% Lymphomas 41% 100% * 0% 20% 40% 60% 80% 100% 120% % of patients survival * P < 0.05 Cornely O, et al. Poster P122. 2nd Advances Against Aspergillosis, Athens, Greece, Feb 2006.

Does Prior Antifungal Therapy Affect Outcomes with Liposomal Amphotericin B Therapy? Cornely O, et al. Poster #M-885, ICAAC 2006.

Response and Survival with L-AMB Was Not Affected by Prior Azole or Voriconazole Use 100% Favorable Response 100% Survival 80% 80% 64% 66% 72% 64% % of patie ents 60% 40% 49% 50% 46% 36% % of patie ents 60% 40% 20% 20% 0% Prior Az No prior Az Prior Vori No Prior Vori 0% Prior Az No prior Az Prior Vori No Prior Vori Cornely O, et al. Poster #M-885, ICAAC 2006.

Overall Mortality Time to Death 1.00 Proba bility of Surviva l 0.75 0.50 0.25 Posaconazole Standard azoles P =.003* 0.00 0 20 40 60 80 100 Days after Randomization Censoring time is last contact or day 100.

Overall Mortality Time to Death 1.00 l Surviva bility of 0.75 0.50 log rank, P =.035 Proba 0.25 Posaconazole Standard azoles 0.00 0 20 40 60 80 100 Days after Randomization Censoring time is last contact or day 100.

Survival until Day 7 post EOT (MITT) 100% % surv vival 90% 80% 70% p=0.044 Caspofungin, n=556 L-AmB, n=539 60% 50% 0 10 20 30 40 50 60 Days on study

Global the Aspergillus Study Group and the

Patients with Satisfactory Treatment Response Categorized by Baseline CT Findings (adapted from Tom Patterson) Sati isfactory Response (CR/PR) 100 80 60 40 20 0 53 45 32 19 67 60 37 All Patients Definite Probable Probable (Radiology alone) Pr reemptive 44 44 23 Non-MITT Voriconazole Amphotericin B Herbrecht R et al NEJM 2002;347:408-15; Patterson TF et al, Clin Infect Dis 2005;41:1448-52; Greene R et al. ECCMID 2003

Cornely et al. CID 2007. 2007; 44:1289 97.

Favorable Overall Response: No Significant Differences between Treatment Groups Preemptive No differences are statistically significant Cornely O. et al. Blood 2005; 106:900a, Abstract 3222.

Caspofungin for IA in Hematological Patients (EORTC) Multicenter, open, phase II First-line therapy Probable and proven invasive aspergillosis First study to apply strict EORTC/MSG diagnostic criteria Response rate (%) in the 30s.

Conclusions Voriconazole and liposomal amphotericin B both are AI recommended for 1st line treatment of IA. Diagnostic options are still very limited, making overtreatment clinical practice. Early treatment yields the highest rates in response and survival. The clinical field moves away from treating proven/probable IA.